cTnI Cartridge

About cTnI

With i-STAT cardiac troponin I (cTnI), healthcare professionals can obtain quantitative measurement of cardiac troponin I (cTnI) in ten minutes without leaving the patient's side. By incorporating i-STAT cTnI early in the patient experience, measurements of cardiac troponin I can improve diagnosis and treatment of myocardial infarction (MI) and aid in the risk stratification of patients with acute coronary syndromes (ACS) with respect to their relative risk of mortality.

Watch this short patient testimonial featuring George Hertner, MD, FACEM to see how process efficiencies achieved with i-STAT cTnI helped improve a particular patient’s care in his Emergency Department.

For an overview of i-STAT System test cartridges, browse the Test Cartridge Menu.

clock-ctni.png

Results in 10 Minutes

Providing lab-quality results fast when every
minute counts.

e-Abbott

Ordering cTnI cartridges and other i-STAT System products is easy using our e-Abbott portal.

Order cTnI

Cartridge Details
 

cardiac_marker-icon.pngCardiac Markers
 
cTnI
Cardiac Troponin I (cTnI)

cTnI - INTENDED USE
The i-STAT cardiac troponin I (cTnI) test is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTnI) in whole blood or plasma. Measurements of cardiac troponin I are used in the diagnosis and treatment of myocardial infarction and as an aid in the risk stratification of patients with acute coronary syndromes with respect to their relative risk of mortality
The i-STAT cTnI cartridge meets the ACC/AHA guideline of 60-minute turnaround time 98% of the time, compared with 53% for the central lab1
Provides lab-quality results,2 which can improve adoption of serial cardiac marker testing
The 2012 Third Universal Definition of Myocardial Infarction recognizes troponin as the biomarker of choice3
Use of bedside testing in the ED has been shown to reduce:
  • time to anti-ischemic therapy by approximately 45 minutes4
  • time to discharge by 24 minutes1
  • ED length of stay by 1.9 hours5
All LeftSide_chem8.png

Description:

Rapid triage of chest pain patients, including those with ACS

Sample Size:

17μL

Sample type:

 

  • Heparinized whole blood or plasma samples collected in syringes or evacuated tubes containing lithium heparin, or
  • Non-heparinized whole blood samples tested within one minute of drawing from a patient into a plastic syringe or plastic evacuated tube containing no additives

 

Part Number:

06P23-25

Expected Values
 

cardiac_marker-icon.pngCardiac Markers
 
  Reportable Range Reference Range (Venous)
Cardiac Troponin I (cTnI) 0.00-50.00 ng/mL 0.00-0.08 ng/mL*
    * Represents the 0 to 99% range of results.

References: 1. ACEP Task Force Report on Boarding. Emergency Department Crowding: High-Impact Solutions. Irving, Tex: American College of Emergency Physicians; April 2008. 2. Ryan R, Lindsell C, Hollander J, et al. A multicenter randomized controlled trial comparing central laboratory and point-of-care marker testing strategies: The disposition impacted by serial point of care markers in acute coronary syndromes (DISPO-ACS) trial. Ann Emerg Med. 2009;53:321- 328. 3. Third Universal Definition of Myocardial Infarction (MI), Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman and Harvey D. White, Circulation 2012;126:2020-2035 www.scpc.org/resources/PDFs/ThirdUniversalDefinitionofMyocardialInfarction_CIRC2012.pdf 4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-304. 5. Renaud B, Maison P, Ngako A, et al. Impact of point-of-care testing in the emergency department evaluation and treatment of patients with suspected acute coronary syndromes. Acad Emerg Med. 2008;15:216-224.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

Not optimized for your device

The page you are trying to access is best viewed on a desktop or laptop computer.

I want to view this page anyway
Contact us today